Matthew Korenberg - 02 Jan 2024 Form 4 Insider Report for LIGAND PHARMACEUTICALS INC (LGND)

Role
PRESIDENT & CHIEF OPERATING
Signature
By: /s/ Andrew Reardon, Attorney-in-Fact For: Matthew E. Korenberg
Issuer symbol
LGND
Transactions as of
02 Jan 2024
Transactions value $
-$210,928
Form type
4
Filing time
04 Jan 2024, 16:07:14 UTC
Previous filing
06 Dec 2023
Next filing
16 Feb 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction LGND Common Stock Tax liability -$210,928 -2,917 -3% $72.31 94,223 02 Jan 2024 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents shares withheld by the Issuer in payment of the tax liability arising in connection with the settlement of restricted stock units.